Filing Details

Accession Number:
0001209191-24-001486
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-11 18:51:54
Reporting Period:
2024-01-09
Accepted Time:
2024-01-11 18:51:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1601830 Recursion Pharmaceuticals Inc. RXRX Biological Products, (No Disgnostic Substances) (2836) 464099738
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1837016 Y Dean Li C/O Recursion Pharmaceuticals
41 S. Rio Grande Street
Salt Lake City UT 84101
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Disposition 2024-01-09 28,038 $13.65 421,962 No 4 S Indirect By Dean Y. Li 2021 Family Trust
Class A Common Stock Disposition 2024-01-09 962 $14.03 421,000 No 4 S Indirect By Dean Y. Li 2021 Family Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Dean Y. Li 2021 Family Trust
No 4 S Indirect By Dean Y. Li 2021 Family Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Class A Common Stock 1,327,618 Direct
Class A Common Stock 1,422,048 Indirect By Dean Y. Li Revocable Trust
Footnotes
  1. Sales are pursuant to a 10b5-1 trading plan established by the Trust on August 22, 2023.
  2. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13 to $13.99 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
  3. The shares are held by the Dean Y. Li 2021 Family Trust, of which the Reporting Person's spouse serves as trustee.
  4. The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $14 to $14.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.